Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07072104
Enrolling by invitation Not applicable

Reading-FREE Markers for Early Detection of Developmental Dyslexia

NCT07072104 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2025-07
Last updated
2025-07-18

Condition(s) studied

Preterm BirthDevelopmental Dyslexia

Investigational drug(s) / intervention(s)

Multidomain Neuropsychological and Reading-Free Screening Tool (RSFT) Assessment Battery - Grade 2MRI - Grade 2Multidomain Neuropsychological and Reading-Free Screening Tool (RSFT) Assessment Battery - Grade 3

Multidomain Neuropsychological and Reading-Free Screening Tool (RSFT) Assessment Battery - Grade 2: * Behavioral testing: standardized neuropsychological battery (language, reading, attention, memory, intelligence) * RFST: Reading-Free Screening Tool assessing pre-reading cognitive markers

MRI - Grade 2: ■ Diagnostic Imaging: structural and resting-state functional MRI (T1-weighted and rs-fMRI)

Multidomain Neuropsychological and Reading-Free Screening Tool (RSFT) Assessment Battery - Grade 3: * Behavioral testing: standardized neuropsychological battery (language, reading, attention, memory, intelligence) * RFST: Reading-Free Screening Tool assessing pre-reading cognitive markers

Study summary

This study aims to identify early signs of developmental dyslexia (DD) and other reading difficulties in children born preterm, using behavioral, cognitive, and brain imaging data collected before reading problems typically become noticeable. Children born very early often face greater risk for reading and learning challenges, but these difficulties are not always detected in time for early support. This research seeks to fill that gap. A group of 30 children born preterm will be followed over time, alongside a control group of 15 children born at term. All children will be assessed during the second and third years of primary school (around ages 6-9). In Grade 2, children will undergo (a) a specially designed digital screening tool for reading difficulties that does not require actual reading (called the RFST), (b) standard tests of reading, language, and attention, and (c) structural and functional brain scans using Magnetic Resonance Imaging (MRI). In Grade 3, the children will be reassessed using the RFST and the cognitive and language tests. The goal is to identify specific behavioral and brain-based markers-particularly patterns of brain connectivity-that are already present in Grade 2 and can predict which children will go on to show reading difficulties in Grade 3. By comparing data from preterm and term-born children, researchers aim to discover early warning signs that are specific to children born preterm. By detecting these risks early, before reading delays become severe, the study hopes to guide new tools for screening and early intervention, tailored specifically to the unique developmental paths of children born preterm. This could help prevent later academic struggles and promote better long-term outcomes.

Eligibility

Sex
ALL
Min age
6 Years
Max age
9 Years
Healthy volunteers
Accepted
Inclusion Criteria: For Preterm-Born (PTB) Children: * Born preterm (i.e., gestational age \< 39 weeks) * Aged between 6 and 9 years at enrollment * Absence of structural brain lesions (as assessed by prior clinical imaging) * Italian as the first language (L1) * Right-hand dominant * Male or female For At-Term-Born (ATB) Children: * Born at term (i.e., gestational age between 39 and 42 weeks) * Aged between 6 and 9 years at enrollment * Absence of structural brain lesions (as assessed by prior clinical imaging) * Italian as the first language (L1) * Right-hand dominant * Male or female Exclusion Criteria: For Preterm-Born (PTB) Children: * History of congenital infections * Diagnosis of Multiple Congenital Anomalies Syndrome * Presence of focal intracerebral parenchymal lesions * Pathological findings on conventional MRI For At-Term-Born (ATB) Children: * Presence of first-degree relatives diagnosed with developmental dyslexia (DD) * Diagnosis of other learning or behavioral disorders * Contraindications to MRI (e.g., metal implants, severe claustrophobia)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Neuroradiology Unit and CERMAC, IRCCS Ospedale San Raffaele Milan MI

More Università Vita-Salute San Raffaele trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07072104 on ClinicalTrials.gov ↗ ← All trials in Italy